These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15574753)

  • 1. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice.
    Hao C; Song JH; Hsi B; Lewis J; Song DK; Petruk KC; Tyrrell DL; Kneteman NM
    Cancer Res; 2004 Dec; 64(23):8502-6. PubMed ID: 15574753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity.
    Higuchi H; Bronk SF; Taniai M; Canbay A; Gores GJ
    J Pharmacol Exp Ther; 2002 Nov; 303(2):461-7. PubMed ID: 12388624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
    Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
    Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
    Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
    Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
    Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of TRAIL and its receptors in viral hepatitis.
    Mundt B; Kühnel F; Zender L; Paul Y; Tillmann H; Trautwein C; Manns MP; Kubicka S
    FASEB J; 2003 Jan; 17(1):94-6. PubMed ID: 12475902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand.
    Jo M; Kim TH; Seol DW; Esplen JE; Dorko K; Billiar TR; Strom SC
    Nat Med; 2000 May; 6(5):564-7. PubMed ID: 10802713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
    Walczak H; Miller RE; Ariail K; Gliniak B; Griffith TS; Kubin M; Chin W; Jones J; Woodward A; Le T; Smith C; Smolak P; Goodwin RG; Rauch CT; Schuh JC; Lynch DH
    Nat Med; 1999 Feb; 5(2):157-63. PubMed ID: 9930862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes.
    Lin T; Gu J; Zhang L; Huang X; Stephens LC; Curley SA; Fang B
    Cancer Res; 2002 Jul; 62(13):3620-5. PubMed ID: 12097263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis.
    Mace TA; Yamane N; Cheng J; Hylander BL; Repasky EA
    Immunol Invest; 2006; 35(3-4):279-96. PubMed ID: 16916755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.
    Saitou Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Hum Pathol; 2005 Oct; 36(10):1066-73. PubMed ID: 16226105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and antitumor activity of recombinant soluble Apo2 ligand.
    Ashkenazi A; Pai RC; Fong S; Leung S; Lawrence DA; Marsters SA; Blackie C; Chang L; McMurtrey AE; Hebert A; DeForge L; Koumenis IL; Lewis D; Harris L; Bussiere J; Koeppen H; Shahrokh Z; Schwall RH
    J Clin Invest; 1999 Jul; 104(2):155-62. PubMed ID: 10411544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes.
    Armeanu S; Lauer UM; Smirnow I; Schenk M; Weiss TS; Gregor M; Bitzer M
    Cancer Res; 2003 May; 63(10):2369-72. PubMed ID: 12750253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects.
    Baader E; Toloczko A; Fuchs U; Schmid I; Beltinger C; Ehrhardt H; Debatin KM; Jeremias I
    Cancer Res; 2005 Sep; 65(17):7888-95. PubMed ID: 16140959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor {alpha}-related apoptosis-inducing ligand/anticancer drug combinations.
    Meurette O; Lefeuvre-Orfila L; Rebillard A; Lagadic-Gossmann D; Dimanche-Boitrel MT
    Clin Cancer Res; 2005 Apr; 11(8):3075-83. PubMed ID: 15837763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
    Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S
    Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.
    Ichikawa K; Liu W; Zhao L; Wang Z; Liu D; Ohtsuka T; Zhang H; Mountz JD; Koopman WJ; Kimberly RP; Zhou T
    Nat Med; 2001 Aug; 7(8):954-60. PubMed ID: 11479629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells.
    Horinaka M; Yoshida T; Shiraishi T; Nakata S; Wakada M; Nakanishi R; Nishino H; Sakai T
    Biochem Biophys Res Commun; 2005 Aug; 333(3):833-8. PubMed ID: 15963948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.
    Michowitz Y; Goldstein E; Roth A; Afek A; Abashidze A; Ben Gal Y; Keren G; George J
    J Am Coll Cardiol; 2005 Apr; 45(7):1018-24. PubMed ID: 15808757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.